Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Rachel J. Perry, Gerald I. Shulman
Journal of Biological Chemistry (2020) Vol. 295, Iss. 42, pp. 14379-14390
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 107
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 72
Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease
Verónica Miguel, Isaac Shaw, Rafael Kramann
Nature Reviews Nephrology (2024)
Closed Access | Times Cited: 18
Diabetic Nephropathy - a Review of Risk Factors, Progression, Mechanism, and Dietary Management
Natesan Vijayakumar, Sungjin Kim
Biomolecules & Therapeutics (2021) Vol. 29, Iss. 4, pp. 365-372
Open Access | Times Cited: 91
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102524-102524
Closed Access | Times Cited: 12
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Sha Chen, Kenneth Overberg, Zakiya Ghouse, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116477-116477
Open Access | Times Cited: 9
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Camilla Anastasio, Isabella Donisi, Vitale Del Vecchio, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Management of Obesity in Cardiovascular Practice
Jean‐Pierre Després, André C. Carpentier, André Tchernof, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 5, pp. 513-531
Open Access | Times Cited: 53
Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials
Rosaria Benedetti, Giuditta Benincasa, Kimberly Glass, et al.
Pharmacological Research (2021) Vol. 175, pp. 106039-106039
Closed Access | Times Cited: 49
Sodium Transporters in Human Health and Disease
Kenneth B. Gagnon, Eric Delpire
Frontiers in Physiology (2021) Vol. 11
Open Access | Times Cited: 43
SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats
Olha Kravtsova, Ruslan Bohovyk, Vladislav Levchenko, et al.
AJP Renal Physiology (2022) Vol. 322, Iss. 6, pp. F692-F707
Open Access | Times Cited: 34
Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
Cheuk To Chung, Ishan Lakhani, Oscar Hou In Chou, et al.
Cancer Medicine (2023) Vol. 12, Iss. 11, pp. 12299-12315
Open Access | Times Cited: 17
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau, Lui Ng, Jason W.H. Wong, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1121-1136
Closed Access | Times Cited: 36
Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway
Jingyi Luo, Pengbo Sun, Xun Zhang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13336-13336
Open Access | Times Cited: 33
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Tsvetalina Tankova, Elżbieta Senkus, Maria Beloyartseva, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1598-1598
Open Access | Times Cited: 28
Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
Cristina Andreea Adam, Răzvan Anghel, Dragoș Traian Marius Marcu, et al.
Life (2022) Vol. 12, Iss. 6, pp. 803-803
Open Access | Times Cited: 27
Metabolic reprogramming heterogeneity in chronic kidney disease
Verónica Miguel, Rafael Kramann
FEBS Open Bio (2023) Vol. 13, Iss. 7, pp. 1154-1163
Open Access | Times Cited: 15
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Jun-Pei Hu, Jianhui Teng, Shan Hui, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29486-e29486
Open Access | Times Cited: 5
Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Zahra Vaziri, Kiarash Saleki, Cena Aram, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115686-115686
Open Access | Times Cited: 12
Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
Lubna Islam, Dhanya Jose, Mohammed Alkhalifah, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 3, pp. 463-474
Open Access | Times Cited: 4
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts
Leigh Goedeke, Yina Ma, Rafael Calais Gaspar, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 24
Open Access | Times Cited: 4
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Relationship of dietary intake and eating behaviors with glycemic control and body weight under long-term treatment with dapagliflozin: an exploratory prospective study
Hisashi Yokomizo, Daiji Kawanami, Noriyuki Sonoda, et al.
Diabetology International (2025)
Closed Access
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
Gilda M. Portalatin, Irene Hong‐McAtee, Anna Burgner, et al.
Frontiers in Pediatrics (2025) Vol. 13
Open Access
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials
Y. Wang, Zonglin Li, Chu Lin, et al.
Expert Review of Clinical Pharmacology (2025)
Closed Access
Page 1 - Next Page

Scroll to top